Celyad Oncology SA - ESG Rating & Company Profile powered by AI
The assessment of Celyad Oncology SA incorporates information from across the web and also from available disclosures by Celyad Oncology SA. Full ESG analysis of Celyad Oncology SA are reached by signing in. Jump to the end of this webpage for potential risks for Celyad Oncology SA based on sector, geography and size.
Celyad Oncology SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.4; made up of an environmental score of 8.0, social score of 6.7 and governance score of 4.6.
6.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 511 | Wakamoto Pharmaceutical Co Ltd | 6.5 | High |
| 511 | X4 Pharmaceuticals Inc | 6.5 | High |
| 535 | Celyad Oncology SA | 6.4 | High |
| 535 | Al Mansour Pharmaceuticals Industries Co | 6.4 | High |
| 535 | Alpine Immune Sciences Inc | 6.4 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Celyad Oncology SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Celyad Oncology SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Celyad Oncology SA report the average age of the workforce?
Sign up for free to unlockDoes Celyad Oncology SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Celyad Oncology SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Celyad Oncology SA disclose cybersecurity risks?
Sign up for free to unlockDoes Celyad Oncology SA offer flexible work?
Sign up for free to unlockDoes Celyad Oncology SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Celyad Oncology SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Celyad Oncology SA conduct supply chain audits?
Sign up for free to unlockDoes Celyad Oncology SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Celyad Oncology SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Celyad Oncology SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Celyad Oncology SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Celyad Oncology SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Celyad Oncology SA disclose water use targets?
Sign up for free to unlockDoes Celyad Oncology SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Celyad Oncology SA have a product recall in the last two years?
Sign up for free to unlockDoes Celyad Oncology SA disclose incidents of discrimination?
Sign up for free to unlockDoes Celyad Oncology SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Celyad Oncology SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Celyad Oncology SA disclose parental leave metrics?
Sign up for free to unlockDoes Celyad Oncology SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Celyad Oncology SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Celyad Oncology SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Celyad Oncology SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Celyad Oncology SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Celyad Oncology SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Celyad Oncology SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Celyad Oncology SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Celyad Oncology SA disclose its waste policy?
Sign up for free to unlockDoes Celyad Oncology SA report according to TCFD requirements?
Sign up for free to unlockDoes Celyad Oncology SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Celyad Oncology SA disclose energy use targets?
Sign up for free to unlockDoes Celyad Oncology SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Celyad Oncology SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Celyad Oncology SA
These potential risks are based on the size, segment and geographies of the company.
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.